Estrogen receptor-a: molecular mechanisms and interactions with the ubiquitin proteasome system

被引:2
作者
Stanisic, Vladimir [1 ]
Lonard, David M. [1 ]
O'Malley, Bert W. [1 ]
机构
[1] Baylor Coll Med, Mol & Cellular Biol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
coactivators; degradation; E3; ligase; estrogen receptor; proteasome; transcription;
D O I
10.1515/HMBCI.2010.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Estrogen receptor-a (ERa) is a protein with a long history of study that precedes the advent of modern molecular biology. Over the course of 50 years, ERa has been increasingly recognized as a prominent model for the study of the mechanism of gene transcription in vertebrates. It also serves as a regulatory molecule for numerous physiological and disease states. Several fundamental insights have been made using ERa as a model protein, from the discovery that endocrine hormones elicit gene transcription to our understanding of the relationship between ERa-mediated transcription and transcription factor degradation by the ubiquitin proteasome system (UPS). Understanding of receptor protein degradation developed alongside other aspects of its molecular biology, from early observations in the 1960s that ERa is degraded on hormone treatment to the current understanding of ERa transcriptional regulation by the UPS. Here, we present the concept of ERa turnover from the perspective of the historical development of this notion and highlight some of the latest discoveries regarding this process. We discuss the logic and significance of ERa degradation pathways in the context of cell and whole-organism homeostasis.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 96 条
[1]   The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines [J].
Adams, Brian D. ;
Furneaux, Henry ;
White, Bruce A. .
MOLECULAR ENDOCRINOLOGY, 2007, 21 (05) :1132-1147
[2]   Proteasome-mediated proteolysis of estrogen receptor: A novel component in autologous down-regulation [J].
Alarid, ET ;
Bakopoulos, N ;
Solodin, N .
MOLECULAR ENDOCRINOLOGY, 1999, 13 (09) :1522-1534
[3]   AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[4]  
Ballinger CA, 1999, MOL CELL BIOL, V19, P4535
[5]   THE TAU-4 ACTIVATION DOMAIN OF THE THYROID-HORMONE RECEPTOR IS REQUIRED FOR RELEASE OF A PUTATIVE COREPRESSOR(S) NECESSARY FOR TRANSCRIPTIONAL SILENCING [J].
BANIAHMAD, A ;
LENG, XH ;
BURRIS, TP ;
TSAI, SY ;
TSAI, MJ ;
OMALLEY, BW .
MOLECULAR AND CELLULAR BIOLOGY, 1995, 15 (01) :76-86
[6]   Methylation at arginine 17 of histone H3 is linked to gene activation [J].
Bauer, UM ;
Daujat, S ;
Nielsen, SJ ;
Nightingale, K ;
Kouzarides, T .
EMBO REPORTS, 2002, 3 (01) :39-44
[7]   Estrogen receptor-α hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome [J].
Berry, Nicholas B. ;
Fan, Meiyun ;
Nephew, Kenneth P. .
MOLECULAR ENDOCRINOLOGY, 2008, 22 (07) :1535-1551
[8]  
BULLER RE, 1976, J BIOL CHEM, V251, P5178
[9]   CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor α by the proteasome [J].
Calligé, M ;
Kieffer, I ;
Richard-Foy, H .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (11) :4349-4358
[10]   NUCLEAR FACTOR RIP140 MODULATES TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR [J].
CAVAILLES, V ;
DAUVOIS, S ;
LHORSET, F ;
LOPEZ, G ;
HOARE, S ;
KUSHNER, PJ ;
PARKER, MG .
EMBO JOURNAL, 1995, 14 (15) :3741-3751